当前位置: X-MOL 学术In Vivo › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy
In Vivo ( IF 2.3 ) Pub Date : 2021-01-01 , DOI: 10.21873/invivo.12271
Akihiro Nishiyama 1 , Yukiko Staub 2 , Yukio Suga 2 , Mikiya Fujita 2 , Azusa Tanimoto 3 , Koushiro Ohtsubo 3 , Seiji Yano 3
Affiliation  

Background/Aim: Reportedly, sarcopenia and nutritional status are associated with prognosis in cancer patients. However, data regarding the relationship of these factors with advanced thyroid cancer patients receiving molecular targeted therapy remains scarce. Therefore, we investigated the relationship between nutritional assessment, as well as sarcopenia, and prognosis in patients with advanced thyroid cancer undergoing molecular targeted therapy. Patients and Methods: In this retrospective study, sarcopenia and several markers of nutritional status were assessed in advanced thyroid cancer patients at the Kanazawa University Hospital, before the introduction of molecular targeted therapy. Results: Advanced thyroid cancer patients with sarcopenia presented a worse prognosis than those without sarcopenia. Additionally, sarcopenia strongly correlated with several markers of nutritional status, such as albumin, prognostic nutrition index, and Glasgow prognostic score. Conclusion: Sarcopenia could be a prognostic factor in patients with advanced thyroid cancer receiving molecular targeted therapy.

中文翻译:

少肌症可能影响接受分子靶向治疗的晚期甲状腺癌患者的预后

背景/目的:据报道,肌肉减少症和营养状况与癌症患者的预后相关。然而,关于这些因素与接受分子靶向治疗的晚期甲状腺癌患者之间关系的数据仍然很少。因此,我们调查了接受分子靶向治疗的晚期甲状腺癌患者的营养评估以及肌肉减少症与预后之间的关系。患者和方法:在这项回顾性研究中,在引入分子靶向治疗之前,在金泽大学医院对晚期甲状腺癌患者进行了肌肉减少症和几种营养状况标志物的评估。结果:患有肌肉减少症的晚期甲状腺癌患者的预后比没有肌肉减少症的患者更差。此外,肌肉减少症与几种营养状态标志物密切相关,例如白蛋白、预后营养指数和格拉斯哥预后评分。结论:肌肉减少症可能是晚期甲状腺癌患者接受分子靶向治疗的预后因素。
更新日期:2021-01-01
down
wechat
bug